🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "major milestone" in the effort against drug-resistant strains of the pathogen, according to scientists.

A Worldwide Health Concern

Gonorrhoea infections are increasing around the world, with estimates suggesting in excess of 82 million new cases each year. Particularly high rates are reported in Africa and countries within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary step in the face of rising global incidence, increasing antimicrobial resistance and the highly restricted available drugs currently available.”

Health officials are particularly alarmed about the increase in antibiotic-resistant strains. The global health body has designated it as a "priority pathogen". Ongoing monitoring found that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Gain Authorization

Zoliflodacin, marketed under the name a brand name, was authorized by the US FDA in December for use against gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers anticipate that specific application of this new drug will help hinder the development of resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, also received approval in close succession. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to develop it.

“This milestone represents a significant shift in the therapy of highly resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Testing Data and Worldwide Availability

According to findings released by a prominent scientific publication, the new drug eradicated the vast majority of cases of the STI. This places it at an similar efficacy with the typical regimen, which combines an injection and a pill. The study enrolled over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the authority to register and commercialise the drug in numerous low-income and middle-income countries.

Medical professionals on the front lines have expressed hope. The availability of a one-pill regimen like this is seen as a "revolutionary step" for public health efforts. This is considered vital to alleviate the strain of the infection for people and to prevent the spread of untreatable gonorrhoea globally.